XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Fair Value - Additional Information (Details) |  |  |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2024 USD ($) | Jul. 31, 2023 USD ($) Installment | Apr. 07, 2022 | Jan. 01, 2022 USD ($) | Oct. 31, 2024 USD ($) | Jul. 31, 2024 USD ($) Installment | Apr. 30, 2024 USD ($) Installment | Apr. 30, 2022 USD ($) Installment | Jan. 31, 2016 USD ($) shares | Dec. 31, 2024 USD ($) Installment | Dec. 31, 2023 USD ($) shares | Dec. 31, 2018 USD ($) Installment shares | Nov. 21, 2022 shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of warrant liability |  |  |  |  |  |  |  |  |  |  | $ 1,274,000 |  |
2018 Notes | Series G Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant issued to purchase shares | shares |  |  |  |  |  |  |  |  |  |  | 613,333 |  |
Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense due to passage of time and fixed payment schedule |  |  |  |  |  |  |  |  |  | $ 1,100,000 | $ 3,900,000 |  |
Warrant Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant issued to purchase shares | shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000
Change in fair value of warrant liability |  |  |  |  |  |  |  |  |  | 0 | (1,300,000) |  |
Contingent Value Rights | Series F Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of warrant liability |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |
Percentage of net proceeds |  |  |  |  |  |  |  |  | 15.00% |  |  |  |
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent value rights interest rate |  |  |  |  |  |  |  |  | 0.00375% |  |  |  |
Shares issued | shares |  |  |  |  |  |  |  |  | 3,999 |  |  |  |
Drug interest rate percentage |  |  |  |  |  |  |  |  | 15.00% |  |  |  |
Contingent value rights |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |
Integrated Diagnostics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Exit fee payment | $ 6,100,000 |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostics, Inc | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition description |  |  |  |  |  |  |  |  |  | required additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month |  |  |
Business acquisition contingent consideration gross margin target |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |
Business acquisition contingent consideration gross margin target period |  |  |  |  |  |  |  |  |  |  |  | 7 years |
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration number of installments | Installment |  | 3 |  |  |  | 1 | 1 | 5 |  |  |  |  |
Milestone payment |  | $ 3,000,000 |  |  |  | $ 8,400,000 | $ 5,000,000 | $ 2,000,000 |  |  |  |  |
Percentage of interest on installment payments |  |  | 10.00% |  |  |  |  |  |  |  |  |  |
Exit fee payment |  |  |  |  | $ 6,100,000 |  |  |  |  |  |  |  |
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition description |  |  |  |  |  |  |  |  |  | If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million. |  |  |
Contingent consideration shares | shares |  |  |  |  |  |  |  |  |  |  |  | 2,520,108 |
Contingent consideration number of installments | Installment |  |  |  |  |  |  |  |  |  | 6 |  | 8 |
Contingent consideration arrangements, common shares, redemption amount |  |  |  | $ 4,600,000 |  |  |  |  |  |  |  | $ 37,000,000 |
Repayments of debt |  | 9,300,000 |  |  |  |  |  |  |  |  |  |  |
Business combination contingent consideration final payment |  | $ 37,000,000 |  |  |  |  |  |  |  |  |  |  |
Contingent consideration cash payment |  |  |  |  |  |  |  |  |  |  |  | $ 37,000,000 |
Investment, Type [Extensible Enumeration] |  |  |  |  |  |  |  |  |  |  |  | Repurchase |
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration | Repurchase |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration number of installments | Installment |  |  |  |  |  |  |  |  |  |  |  | 2 |
Minimum | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range |  |  |  |  |  |  |  |  |  | 11.00% |  |  |
Maximum | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range |  |  |  |  |  |  |  |  |  | 16.00% |  |  |

X
- Definition Business acquisition contingent consideration gross margin target period. + References No definition available. + Details
Name: | bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
Namespace Prefix: | bdsx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition contingent consideration number of installments. + References No definition available. + Details
Name: | bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments
Namespace Prefix: | bdsx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business combination contingent consideration arrangements common shares redemption amount. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination contingent consideration final payment. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationFinalPayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination contingent consideration shares. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationShares
Namespace Prefix: | bdsx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent value rights fair value disclosure. + References No definition available. + Details
Name: | bdsx_ContingentValueRightsFairValueDisclosure
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights interest rate. + References No definition available. + Details
Name: | bdsx_ContingentValueRightsInterestRate
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Drug interest rate percentage. + References No definition available. + Details
Name: | bdsx_DrugInterestRatePercentage
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exit fee payment. + References No definition available. + Details
Name: | bdsx_ExitFeePayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest expense due to passage of time and fixed payment schedule. + References No definition available. + Details
Name: | bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | bdsx_MilestonePayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of interest on contingent consideration. + References No definition available. + Details
Name: | bdsx_PercentageOfInterestOnContingentConsideration
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net proceeds. + References No definition available. + Details
Name: | bdsx_PercentageOfNetProceeds
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of probabilities of contingent consideration successful achievement milestone discount rates range. + References No definition available. + Details
Name: | bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_CashAcquiredFromAcquisition
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details
Name: | us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 + Details
Name: | us-gaap_InvestmentTypeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |